Covid19

ICGEB Trieste, Italy is pleased to announce that it is coordinating a project to bring SARS-CoV-2 testing materials from New England BioLabs (NEB^®) to countries in need in Africa, with support from the Bill & Melinda Gates Foundation.

Investigations of deceased COVID-19 patients have shed light on possible lung damage caused by the virus. The latest publication by Mauro Giacca, Serena Zacchigna, and team reports.

MSC Seashore is the first cruise liner to feature this advanced air sanitation technology developed by Fincantieri in cooperation with the ICGEB.

The ICGEB is providing links and publishing updates from its network in Member States on the Covid-19/SARS-CoV-2 actions being undertaken across the globe on this page for reference.

More than 100 COVID-19 research project proposals were submitted in 2020 under the ICGEB CRP Programme call.

A recent scientific collaboration of the Molecular Virology Lab reveals that a physiological derivative of cholesterol blocks the COVID-19 virus, with important implications for COVID-19 therapy.

Organised on behalf of the Italian Ministry of Foreign Affairs, the Italian Ambassador to India, Vincenzo de Luca, and the Ambassador of India to Italy, Reenat Sandhu, the Webinar on Strategic Cooperation on COVID19 and Bilateral Funding Opportunities took place on 14 July 2020.

Dr. Alessandro Marcello presented the latest research and developments from Covid-19 research at ICGEB at the UN DESA / DSDG Webinar on 10 June 2020.

Studies conducted in collaboration with ICGEB, Italy prove instrumental in initiating Phase II clinical trial on AQCH, a phytopharmaceutical drug, as potential treatment for COVID-19 patients.

COVID-19 caught researchers short. Its rampant spread left no time to target studies through rational drug design approaches. The National Research Council, the largest public research institution in Italy has joined forces with the Molecular Virology lab in Trieste, to search for a drug able to eliminate Coronavirus: this is the FARMACOVID project.

Recent studies at ICGEB New Delhi in the battle against Covid19 are leading to further exploration of experimental validation and therapeutic possibilities and have been submitted for funding to BIRAC under a call to fight the pandemic.